Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia

Molecular Psychiatry

Volumn 6, Issue 2, 2001, Pages 230-234

  Basile, V S ^a   Ozdemir, V ^a,b   Masellis, M ^a   Meltzer, H Y ^c   Lieberman, J A ^d   Potkin, S G ^e   Macciardi, F M ^a   Petronis, A ^a   Kennedy, J L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotics; Genetic association; Genetic polymorphism; HTR2A; Receptor; Serotonin; Tardive dyskinesia

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CHLORPROMAZINE; DNA; NEUROLEPTIC AGENT; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE;

ADULT; ARTICLE; DRUG INDUCED DISEASE; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC REGULATION; GENETIC RISK; GENETIC VARIABILITY; GENOME IMPRINTING; GENOTYPE; HISTOGRAM; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR GENE; SCHIZOPHRENIA; SCORING SYSTEM; SEROTONINERGIC SYSTEM; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; GENETIC MARKERS; HUMANS; MALE; POLYMORPHISM, GENETIC; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SCHIZOPHRENIA;

EID: 0035116425     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000847     Document Type: Article

References (25)

1. The treatment of tardive dyskinesia and tardive dystonia
2. Predictors of the course of tardive dyskinesia in patients receiving neuroleptics
3. Familial occurrence of tardive dyskinesia
4. Familial tardive dyskinesia
5. The expression of schizophrenia, affective disorder and vulnerability to tardive dyskinesia in an extensive pedigree
6. Possible genetic factors underlying the pathophysiology of tardive dyskinesia
7. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia
8. Manganese superoxide dismutase gene polymorphism and schizophrenia. Relation to tardive dyskinesia
9. Application of pharmacogenetics of schizophrenia: Emerging insights from studies of clozapine response and tardive dyskinesia
10. Association of the Mscl polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia
11. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia
12. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
13. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype
14. The role of serotonin in antipsychotic drug action
15. Facilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra
16. Serotonin 5-HT2A receptors: Molecular biology and mechanisms of regulation
17. Classification of typical and atypical antipsychotic drugs on the basis of dopamine-D-1, -D-2, and serotonin-2 pKi values
18. Research diagnoses for tardive dyskinesia
19. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients
20. Genetic dissection of complex traits
21. The genes for major psychosis. Aberrant sequence or regulation?
22. A rapid nonenzymatic method for the preparation of HMW DNA from blood for RFLP studies
23. An Mspl polymorphism in the human serotonin receptor gene (HTR2): Detection by DGGE and RFLP analysis
24. A naturally occurring amino acid substitution of the human serotonin 5-HT2A receptor influences amplitude and timing of intracellular calcium mobilization
25. Genetic variation of the 5-HT2A receptor and response to clozapine